Oric Pharmaceuticals (ORIC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.38
- Estimate
- -$0.36
- Surprise
- -4.6%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Oric Pharmaceuticals (ORIC) reported a wider loss than forecast — diluted EPS of -$0.38 against the -$0.36 estimate (a 4.6% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ORIC Sell at 5.4/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -4.6% surprise compares with a +6.2% four-quarter average. Next scheduled report: 2026-11-12.
What argues against it
- Concentration risk — Pipeline: rinzimetostat and enozertinib
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 2.1), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.87
- Price target
- $17.98
- Stop
- $12.13
- Upside to target
- +39.7%
- Reward-to-risk
- 3.8:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
ORIC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.32B
- P/E (fwd)
- -7.9
- 52-week range
- $7.23–$14.93
- Off 52-week high
- 13.8%
- RSI (14)
- 45
- Volume vs avg
- 0.58×
- Score today
- 5.4/10